ArticleThe Journal of experimental medicine2011
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Article in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 461 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
461 citing papers in PubMed, 695 citations in OpenAlex.
- Optimizing immunotherapy for head and neck squamous cell carcinoma: recent advances and future directions.Annals of medicine · 2026Review
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- VISTA drives tumour-intrinsic proliferation in mesothelioma cells.British journal of cancer · 2026Article
- Deciphering the mechanisms of macrophage polarization through comprehensive analysis of cellular and cell-surface protein glycosylation.Nature communications · 2026Article
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.Cancer immunology research · 2026Article
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.Journal of cancer research and clinical oncology · 2026Review
- Differential expression of immune checkpoint VISTA in inflammatory skin diseases.The Journal of investigative dermatology · 2026Article
- VISTA Deficiency Exacerbates Autoimmune Uveitis by Promoting Microglial Activation via the TLR4/MyD88/NF-κB Pathway.Investigative ophthalmology & visual science · 2026Article
- Spatial analyses implicate high stromal tumour-infiltrating CD8Nature communications · 2026Article
- PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression.Journal of translational medicine · 2026Article
- LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.iScience · 2026Article
- Single-cell transcriptomics reveals pediatric immune responses to COVID-19 vaccination.iScience · 2026Article
- VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma.Journal for immunotherapy of cancer · 2026Article
- Recent research progress and clinical status of immunotherapy for colorectal cancer.Journal of advanced research · 2026Review
- Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer.British journal of cancer · 2026Article
- T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses.The Journal of clinical investigation · 2026Article
- VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity.Nature communications · 2026Article
- VISTA: bridging gaps in cancer immunotherapy.Discover oncology · 2026Review
401 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
The immunoglobulin (Ig) superfamily consists of many critical immune regulators, including the B7 family ligands and receptors. In this study, we identify a novel and structurally distinct Ig superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated V-domain Ig suppressor of T cell activation (VISTA). VISTA is primarily expressed on hematopoietic cells, and VISTA expression is highly regulated on myeloid antigen-presenting cells (APCs) and T cells. A soluble VISTA-Ig fusion protein or VISTA expression on APCs inhibits T cell proliferation and cytokine production in vitro. A VISTA-specific monoclonal antibody interferes with VISTA-induced suppression of T cell responses by VISTA-expressing APCs in vitro. Furthermore, anti-VISTA treatment exacerbates the development of the T cell-mediated autoimmune disease experimental autoimmune encephalomyelitis in mice. Finally, VISTA overexpression on tumor cells interferes with protective antitumor immunity in vivo in mice. These findings show that VISTA, a novel immunoregulatory molecule, has functional activities that are nonredundant with other Ig superfamily members and may play a role in the development of autoimmunity and immune surveillance in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.